Real-world safety and effectiveness study of a relapsing MS treatment

This is a real-world registry study that will follow about 2,000 people with relapsing multiple sclerosis (RMS) who are being treated with BRIUMVI® (ublituximab-xiiy), a medication given by IV infusion. The study is designed to track how well this medication works, how safe it is, and what the treatment experience is like for patients receiving it in regular clinical settings rather than in a controlled research environment.

While medications are tested carefully before approval, doctors and patients benefit from understanding how a treatment performs and what the experience is like when many different people use it in real-world conditions. This study will help fill that gap by collecting information about safety, effectiveness, and patient experiences with this medication over time.